logo

Durect Corp. (DRRX)



Trade DRRX now with
  Date
  Headline
7/22/2019 8:04:20 AM DURECT, Gilead Enter License Agreement For Long-Acting Injectable HIV Investigational Product
7/17/2019 8:06:24 AM DURECT Says FDA Agrees To File Full Response To POSIMIR Complete Response Letter
6/27/2019 8:37:16 AM DURECT Announces Submission To FDA Of Full Response To POSIMIR Complete Response Letter
6/20/2019 8:09:56 AM DURECT Announces $15 Mln Registered Direct Offering
6/18/2019 8:08:54 AM DURECT Completes Dosing 90 Mg Cohort Of Severe AH Patients In Ongoing DUR-928 Phase 2a Clinical Trial
3/27/2019 8:03:21 AM DURECT Announces Patient Enrollment In Phase 1b Clinical Trial Of Oral DUR-928 In Patients With NASH
3/21/2019 8:03:44 AM DURECT Begins Patient Dosing In Phase 2a Proof-of-concept Trial With Topical DUR-928
2/27/2019 7:07:46 AM DURECT Corp. Says Plans To Submit To FDA Full Response To POSIMIR Complete Response Letter
12/17/2018 8:24:29 AM DURECT: Felix Theeuwes To Retire As Chairman Of Board And Distinguished Scientist
10/1/2018 8:09:36 AM DURECT Corporation Appoints Michael Arenberg As CFO
8/6/2018 9:22:49 AM DURECT's Licensee Pain Therapeutics Gets Complete Response Letter From FDA For REMOXY ER Extended-Release Capsules CII
7/30/2018 8:08:46 AM DURECT Reports FDA Approval Of Indivior's PERSERIS Extended-Release Injectable Suspension For Schizophrenia In Adults